Managing Taste Changes and Weight Loss During Talquetamab Treatment
Panelists discuss how patients can maintain their nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary adverse effects that improve over time.
EP: 1.Alan's Multiple Myeloma Journey: Facing a New Diagnosis
EP: 2.Connecting With Multiple Myeloma Support Groups and Online Resources
EP: 3.Alan's Treatment Course and Quality-of-Life Goals
EP: 4.Coordinated Health Care Teams and Caregiver Support
EP: 5.Extending Talquetamab Education Beyond the Hospital
EP: 6.Addressing Early Talquetamab Toxicity Concerns
EP: 7.Developing a System-Wide Protocol for Talquetamab Toxicity Management
EP: 8.Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab
EP: 9.Managing Taste Changes and Weight Loss During Talquetamab Treatment
EP: 10.Advice for the Patient Starting Treatment With Talquetamab
EP: 11.Advice for the Caregiver: Be a Patient Advocate
EP: 12.Addressing Common Talquetamab Misunderstandings
Alan Plisskin’s experience with talquetamab included multiple GPRC5D-related toxicities including hand and foot peeling, complete fingernail loss, and some toenail loss, notably without associated pain. Taste changes lasted approximately 2 months, while dry mouth persisted for 6 months, and he experienced rare postinjection fevers. His positive outcome included 15 pounds of weight gain rather than the weight loss commonly associated with taste and appetite changes.
Nutritional management strategies focus on maximizing caloric density when the appetite is compromised, including high-calorie shakes such as Ensure, and adding healthy fats such as avocado to meals. Texture considerations become paramount when taste is altered, with patients often finding satisfaction in crunchy foods such as nuts or creamy textures when traditional flavors are diminished. Food presentation and making meals into "events" can help maintain interest in eating despite taste alterations.
The temporary nature of taste and appetite changes provides hope for patients struggling with these adverse effects during early treatment phases. Plisskin’s transition from every 2 weeks to monthly dosing as his disease responded illustrates how treatment intervals can be extended while maintaining efficacy, potentially reducing the frequency and severity of adverse effects. His testimony that "quality of life after the [adverse] effects is excellent" emphasizes that patients can return to feeling "normal" once the initial wave of toxicities resolves.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
